Patents by Inventor John R. Koenig

John R. Koenig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
    Patent number: 9452986
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 27, 2016
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • SUBSTITUTED CHROMANES AND METHOD OF USE
    Publication number: 20160120841
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: October 28, 2015
    Publication date: May 5, 2016
    Inventors: Philip R. Kym, Xueqing Wang, Xenia B. Searle, Bo Liu, Ming C. Yeung, Robert J. Altenbach, Eric Voight, Andrew Bogdan, John R. Koenig
  • Indazole Ureas and Method of Use
    Publication number: 20160075692
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: September 15, 2015
    Publication date: March 17, 2016
    Applicant: AbbVie Inc.
    Inventors: Jerome F. Daanen, David A. DeGoey, Jennifer M. Frost, John R. Koenig, Steve Latshaw, Mark Matulenko, Marc Scanio, Lei Shi, William H. Bunnelle
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20150218102
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE
    Publication number: 20150210720
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: January 22, 2015
    Publication date: July 30, 2015
    Inventors: Robert J. Altenbach, Huaqing Liu, Bruce Clapham, Ana L. Aguirre, Marlon Cowart, John R. Koenig, Katerina Sarris, Marc J. Scanio, Kerren K. Swinger, Anil Vasudevan, Clara I. Villamil, Kevin R. Woller
  • Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
    Patent number: 8598220
    Abstract: The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: December 3, 2013
    Assignee: AbbVie Inc.
    Inventors: Brian S. Brown, John R. Koenig, Arthur R. Gomtsyan, Chih-Hung Lee
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8487116
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 16, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
    Patent number: 8440691
    Abstract: Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 14, 2013
    Assignee: AbbVie Inc.
    Inventors: Arthur Gomtsyan, Erol K. Bayburt, Robert G. Schmidt, Jr., Chih-Hung Lee, Brian S. Brown, Tammie K. Jinkerson, John R. Koenig, Jerome F. Daanen, Steven P. Latshaw
  • Macrocyclic pyrimidine derivatives
    Patent number: 8436005
    Abstract: Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: May 7, 2013
    Assignee: Abbott Laboratories
    Inventors: Huaqing Liu, Irene Drizin, John R. Koenig, Marlon D. Cowart, Chen Zhao, Brian D. Wakefield, Lawrence A. Black, Robert J. Altenbach
  • PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR
    Publication number: 20120277190
    Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 1, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Kennan C. Marsh, Robert G. Schmidt, JR., Chih-Hung Lee, Weili Wang, Jerome F. Daanen, Brian S. Brown
  • Macrocyclic spiro pyrimidine derivatives
    Patent number: 8278313
    Abstract: Macrocyclic Spiro pyrimidine compounds of formula (I): compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: October 2, 2012
    Assignee: Abbott Laboratories
    Inventors: Huaqing Liu, John R. Koenig, Marlon D. Cowart, Lawrence A. Black
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8247413
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: August 21, 2012
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley Didomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Prodrugs of compounds that inhibit TRPV1 receptor
    Patent number: 8232309
    Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: July 31, 2012
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Kennan C. Marsh, Robert G. Schmidt, Jr., Chih-Hung Lee, Weili Wang, Jerome F. Daanen, Brian S. Brown
  • FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20120190845
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Application
    Filed: November 9, 2011
    Publication date: July 26, 2012
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chamboumier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
  • Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 8071762
    Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: December 6, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
  • Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
    Patent number: 8026256
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: September 27, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee
  • TRPV1 antagonists
    Patent number: 7998993
    Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: August 16, 2011
    Assignee: Abbott Laboratories
    Inventors: Richard J. Perner, John R. Koenig, Stanley DiDomenico, Jr., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight
  • CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF
    Publication number: 20110152250
    Abstract: Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
    Type: Application
    Filed: September 3, 2010
    Publication date: June 23, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur Gomtsyan, Erol K. Bayburt, Robert G. Schmidt, JR., Chih-Hung Lee, Brian S. Brown, Tammie K. Jinkerson, John R. Koenig, Jerome F. Daanen, Steven P. Latshaw
  • ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF
    Publication number: 20110144057
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 16, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
  • Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
    Patent number: 7902236
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: March 8, 2011
    Assignee: Abbott Laboratories
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee